Package Leaflet: Information for the User
Rivaroxaban TAD 10 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet:
Rivaroxaban TAD contains the active substance rivaroxaban and is used in adults to:
Rivaroxaban belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban TAD
Do not take this medication and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Be careful with Rivaroxaban TAD
Tell your doctor if you have any of these situationsbefore taking this medication. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery
Children and adolescents
Rivaroxaban TAD 10 mg film-coated tablets EFG are not recommended for children under 18 years of age.There is not enough information about its use in children and adolescents.
Other medications and Rivaroxaban TAD
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those obtained without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing stomach or intestinal ulcers, they will recommend using a preventive treatment for ulcers in addition to this medication.
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of rivaroxaban may be decreased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medication.
If you are pregnant or breastfeeding, do not take this medication. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
This medication may cause dizziness (frequent side effect) or fainting (uncommon side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Rivaroxaban TAD contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 10 mg rivaroxaban tablet once a day.
After at least 6 months of treatment for blood clots, the recommended dose is one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed this medication 10 mg once a day.
Swallow the tablets, preferably with water.
This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take this medication. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor may also administer the crushed tablet of this medication through a gastric tube.
When to take Rivaroxaban TAD
Take one tablet every day, until your doctor tells you to stop.
Try to take one tablet at the same time every day, to help you remember.
Your doctor will decide how long you should continue taking the treatment.
To prevent the formation of blood clots in the veins after hip or knee replacement surgery:
Take the first tablet between 6 and 10 hours after surgery.
If you have undergone major hip surgery, you will usually take tablets for 5 weeks.
If you have undergone major knee surgery, you will usually take tablets for 2 weeks.
If you take more Rivaroxaban TAD than you should
Contact your doctor immediately if you have taken too many tablets of this medication. Taking too much medication increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Rivaroxaban TAD
If you forget to take a dose, take it as soon as you remember. Take the next tablet the next day and, after that, take one tablet every day, as usual.
Do not take a double dose to make up for forgotten doses.
If you stop taking Rivaroxaban TAD
Do not stop taking this medication without talking to your doctor first, as this medication prevents the development of a serious condition.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Like other similar medications to reduce blood clotting, this medication can cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be visible.
Tell your doctor immediately if you experience any of the following symptoms:Signs of bleeding:
Your doctor will decide whether to keep you under closer observation or change your treatment.
Signs of severe skin reaction
The frequency of these side effects is very rare (up to 1 in 10,000 people).
Signs of severe allergic reaction
The frequency of severe allergic reactions is very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible side effects
Frequent(may affect up to 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Rare(may affect up to 1 in 1,000 patients)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data)
Reporting side effects
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging and on each blister, after "EXP". The expiry date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the pharmacy's SIGRE point. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Rivaroxaban TAD
Appearance and Package Contents of the Product
Reddish-brown, round, slightly biconvex film-coated tablets, engraved with the mark "10" on one face of the tablet.
Dimensions: approximate diameter of 6.5 mm.
Rivaroxaban TAD is available in packs containing:
Non-perforated blister: 10, 30, and 100 film-coated tablets.
Perforated unit-dose blister: 10 x 1, 30 x 1, and 100 x 1 film-coated tablets.
A patient alert card is included in each pack of this medicine.
Only some pack sizes may be marketed.
Marketing Authorization Holder
TAD Pharma GmbH, Heinz-Lohmann Straße 5, 27472 Cuxhaven, Germany
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann Straße 5, 27472 Cuxhaven, Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., Calle de Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Member State | Medicine Name |
Denmark | Rivaroxaban TAD 10 mg filmovertrukne tabletter |
Austria | Rivaroxaban HCS 10 mg Filmtabletten |
Spain | Rivaroxaban TAD 10 mg comprimidos recubiertos con película EFG |
Italy | Rivaroxaban Krka 10 mg |
Date of the Last Revision of this Leaflet:February 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/